Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Our decades of proven success come from passionate team members around the globe collaborating to bring the best treatments forward.
Tursi is member of the Ideal Image and Agile Therapeutics Boards of Directors.Ībout Endo Endo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. He holds a Bachelor of Science degree in Chemistry and Biology from Ursinus College a Doctor of Medicine from Medical College of Pennsylvania and performed his residency in Gynecology and Obstetrics at the Johns Hopkins Hospital. Tursi practiced medicine and surgery for over 10 years and created a medical education company, I Will Pass ®, which assisted physicians in the process of board certification. Tursi was the Executive Vice President, R&D, Chief Medical Officer for Antares Pharmaceuticals, Chief Medical Officer at Aralez Pharmaceuticals, Chief Medical Officer and Vice President of Clinical R&D Auxilium Pharmaceuticals, and held positions of increasing responsibility at GlaxoSmithKline, and Procter & Gamble Pharmaceuticals. "I am energized to join the Endo team, and for the opportunity to help advance Endo's on-going transformation and to deliver its strategic priority to expand and enhance its portfolio and help everyone they serve live their best life," said James Tursi, MD. "His broad therapeutic expertise, including in the areas of urology, orthopedics, and pediatric endocrinology, along with his in-depth experience with XIAFLEX ® and collagenase clostridium histolyticum will be invaluable as we pursue our mission to develop and deliver life enhancing products." Tursi is a proven leader with nearly 20 years in the pharmaceutical industry and over 30 total years of medical experience," said Blaise Coleman, Endo's President and Chief Executive Officer. Tursi held the role of Chief Scientific Officer and Executive Vice President of Development at Ferring Pharmaceuticals U.S. He will join the Company's Senior Executive Team and report directly to the Chief Executive Officer.
Tursi as Executive Vice President, Global Research & Development effective January 18, 2022. 11, 2022 /PRNewswire/ - Endo International plc (NASDAQ: ENDP) today announced the appointment of Dr.
0 kommentar(er)
